Stockreport

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include...

Palvella Therapeutics, Inc.  (PVLA) 
PDF Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old Palvella Therapeutics Inc. Mon, February 10, 2025 at 2:00 [Read more]